Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
1.
Br J Dermatol ; 163(2): 329-33, 2010 Aug.
Article de Anglais | MEDLINE | ID: mdl-20426786

RÉSUMÉ

BACKGROUND: Pristinamycin is used for the treatment of Staphylococcus aureus skin infection. Staphylococcus aureus pristinamycin resistance is usually low. The frequency of pristinamycin-resistant S. aureus (PRSA) increased in the Caen University Hospital dermatology department from 1% in 1998 to >11% in 1999-2002. OBJECTIVES: This study aimed to identify the factors associated with PRSA acquisition. METHODS: Incidences of PRSA and pristinamycin consumption were calculated for the dermatology department and for the rest of the hospital from 1997 to 2007. Individual factors of PRSA acquisition in the dermatology department from 2000 to 2001 were analysed in a retrospective case-control study including 23 cases of PRSA skin colonization or infection and 46 controls with pristinamycin-susceptible S. aureus. Clonal relatedness of isolates was analysed by pulsed-field gel electrophoresis and pristinamycin resistance genes were detected by polymerase chain reaction. Conditional logistic regression was performed to analyse the relationship between pristinamycin resistance and epidemiological and microbiological data. RESULTS: PRSA frequency and pristinamycin consumption were significantly higher in the dermatology department than in other hospital departments. Two epidemic clones of two and six isolates were found for periods of 1 and 2 months, respectively. Thirteen of the 23 PRSA isolates (57%), including all isolates of the two epidemic clones, were found 48 h after the hospitalization or later. PRSA was associated with pristinamycin use during the previous year [odds ratio (OR) 5.60, 95% confidence interval (CI) 1.41-22.22], cumulative use of antibiotics exceeding 1 week during the previous year (OR 4.63, 95% CI 1.47-14.54) and methicillin resistance (OR 6.35, 95% CI 1.38-29.15). CONCLUSIONS: Results suggest that antimicrobial selective pressure and microbial cross-transmission are involved in PRSA acquisition.


Sujet(s)
Antibactériens/usage thérapeutique , Infection croisée/épidémiologie , Pristinamycine/usage thérapeutique , Infections à staphylocoques/épidémiologie , Infections cutanées à staphylocoques/épidémiologie , Staphylococcus aureus/effets des médicaments et des substances chimiques , Sujet âgé , Sujet âgé de 80 ans ou plus , Études cas-témoins , Infection croisée/traitement médicamenteux , Infection croisée/microbiologie , Résistance bactérienne aux médicaments , Électrophorèse en champ pulsé , Femelle , Génotype , Humains , Modèles logistiques , Mâle , Tests de sensibilité microbienne , Réaction de polymérisation en chaîne , Études rétrospectives , Infections à staphylocoques/traitement médicamenteux , Infections cutanées à staphylocoques/traitement médicamenteux , Staphylococcus aureus/génétique , Staphylococcus aureus/isolement et purification
2.
Rev Med Interne ; 30(9): 783-8, 2009 Sep.
Article de Français | MEDLINE | ID: mdl-19362394

RÉSUMÉ

INTRODUCTION: In France, unlike other countries, the use of colchicine is preferred to other anti-inflammatory drugs for the treatment of gout. CASE REPORTS: We report a case series of four elderly patients (range from 72 to 83 years of age) who presented with colchicine intoxication, all notified to the Basse-Normandie pharmacovigilance centre in 2007. For each patient, one or more risk factors were identified: renal failure, high initial dosage, absence of laboratory monitoring. CONCLUSION: It would be useful to establish specific guidelines for colchicine use in the elderly population.


Sujet(s)
Colchicine/intoxication , Antigoutteux/intoxication , Goutte/traitement médicamenteux , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Colchicine/administration et posologie , Femelle , France , Antigoutteux/administration et posologie , Humains , Mâle , Intoxication/prévention et contrôle , Polypharmacie , Surveillance post-commercialisation des produits de santé , Facteurs de risque
3.
Eur J Clin Microbiol Infect Dis ; 28(4): 409-13, 2009 Apr.
Article de Anglais | MEDLINE | ID: mdl-18998176

RÉSUMÉ

Sexually transmitted diseases (STD) are a public health issue in prison. As inmates are eventually released, it is also a community concern. There are very few data on the entire spectrum of STDs, particularly condyloma among prisoners. To determine the prevalence of all STDs: infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), Chlamydia trachomatis, Neisseria gonorrhoea, syphilis, and condyloma among entering inmates. A cross-sectional study was conducted in France from November 2000 to June 2003. Male adults entering a prison remand center in Caen had a medical consultation and physical examination including external genital organs and perianal area for condyloma and herpes infection, a urethral swab for Chlamydia trachomatis and Neisseria gonorrhoea detection, and a blood sample for HBV, HCV, HIV, and syphilis serology. Five hundred and ninety-seven inmates agreed to participate in the study. Sixteen percent had at least one STD: 4.0% had condyloma, 4.0% chlamydia infection, and 4.9% were positive for HCV antibodies. Two had early syphilis and 1 had acute HBV, but no HIV infection, neither genital herpes nor gonorrhea. The analysis of the STD risk behaviors did not show any difference between the infected and uninfected participants, except that HCV-positive participants were more likely to be intravenous drug users. Results suggest that a systematic screening of all STDs should be at least proposed to every entering inmate since no demographic or sexual characteristics are consistently associated with STDs.


Sujet(s)
Prisonniers , Maladies sexuellement transmissibles/épidémiologie , Adulte , Études transversales , France , Humains , Mâle , Analyse multifactorielle , Prévalence , Facteurs de risque , Maladies sexuellement transmissibles/microbiologie , Maladies sexuellement transmissibles/virologie , Toxicomanie intraveineuse
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...